Targeting vascular endothelial growth factor: A promising strategy for treating age-related macular degeneration

Drugs and Aging

Volumn 24, Issue 8, 2007, Pages 643-662

  Waisbourd, Michael ^a,b   Loewenstein, Anat ^a   Goldstein, Michaella ^a   Leibovitch, Igal ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; APTAMER; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VITAMIN;

ABRASION; ADVERSE OUTCOME; ANTIANGIOGENIC ACTIVITY; BLOOD PRESSURE; CENTRAL RETINA VEIN OCCLUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON CANCER; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENDOPHTHALMITIS; EYE PAIN; HUMAN; INFLAMMATION; INHIBITION KINETICS; INJECTION SITE REACTION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; MEDICAL LITERATURE; METASTASIS; METHODOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PUNCTATE KERATITIS; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT PLANNING; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION; VITREOUS BODY; VITREOUS FLOATERS; VITREOUS HEMORRHAGE;

AGING; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 34548107597     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724080-00003     Document Type: Review

References (70)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004 Apr 21; 291 (15): 1900-1
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992 Jun; 99 (6): 933-43
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004 Apr; 122 (4): 564-72
4. de Jong PT. Age-related macular degeneration. N Engl J Med 2006 Oct 5; 355 (14): 1474-85
5. Rattner A, Nathans J. Macular degeneration: recent advances and therapeutic opportunities. Nat Rev Neurosci 2006 Nov; 7 (11): 860-72
6. Haddad S, Chen CA, Santangelo SL, et al. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol 2006 Jul-Aug; 51 (4): 316-63
7. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991 Aug; 109 (8): 1109-14
8. Pauleikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina 2005 Dec; 25 (8): 1065-84
9. Age-Related Eye Disease Study Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001 Oct; 119 (10): 1417-36
10. Lim JI. Macular degeneration: the latest in current medical management. Retina 2006 Jul-Aug; 26 (6 Suppl.): S17-20
11. Chakravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006 Sep; 90 (9): 1188-96
12. Schachat AP. New treatments for age-related macular degeneration. Ophthalmology 2005 Apr; 112 (4): 531-2
13. Malecki M, Kolsut P, Proczka R. Angiogenic and antiangiogenic gene therapy. Gene Ther 2005 Oct; 12 Suppl. 1: S159-69
14. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997 Feb; 81 (2): 154-62
15. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 2002 Jul; 64 (1): 162-9
16. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003 Jul; 44 (7): 3186-93
17. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 Nov 18; 285 (21): 1182-6
18. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004 Dec; 56 (4): 549-80
19. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001 Mar; 114 (Pt 5): 853-65
20. Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF system. Front Biosci 1999 Feb 1; 4: D141-52
21. Zachary I. Vascular endothelial growth factor: how it transmits its signal. Exp Nephrol 1998 Nov-Dec; 6 (6): 480-7
22. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005 Mar 23; 293 (12): 1509-13
23. Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2006 Jan; 28 (1): 36-44
24. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 Dec 30; 351 (27): 2805-16
25. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002 Apr; 22 (2): 143-52
26. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000 Dec; 17 (12): 1503-10
27. Vinores SA. Technology evaluation: pegaptanib, Eyetech/Pfizer. Curr Opin Mol Ther 2003 Dec; 5 (6): 673-9
28. Gonzales CR. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005 Oct-Nov; 25 (7): 815-27
29. Chakravarthy U, Adamis AP, Cunningham Jr ET, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration: VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Ophthalmology 2006 Sep; 113 (9): 1508.e1-25. Epub 2006 Jul 7
30. Schuman S, Rogers AH, Duker JS, et al. Six-week outcomes after pegaptanib [letter]. Ophthalmology 2006 Mar; 113 (3): 501
31. Dhalla MS, Blinder KJ, Tewari A, et al. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 2006 Apr; 141 (4): 752-4
32. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 Oct 5; 355 (14): 1419-31
33. Steinbrook R. The price of sight: ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006 Oct 5; 355 (14): 1409-12
34. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002 Mar; 120 (3): 338-46
35. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005 Apr; 123 (4): 509-16
36. Kim IK, Husain D, Michaud N, et al. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 2006 Jan; 47 (1): 357-63
37. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005 Feb; 46 (2): 726-33
38. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 Oct 5; 355 (14): 1432-44
39. Heier JS, Boyer DS, Ciulla TA, et al.; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study [published erratum appears in Arch Ophthalmol 2007 Jan; 125 (1): 138]. Arch Ophthalmol 2006 Nov; 124 (11): 1532-42
40. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006 Sep; 19 (3): 361-72
41. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006 Apr; 113 (4): 642.e1-4. Epub 2006 Feb 14
42. The FDA Safety Information and Adverse Effects Reporting Program. 2007 safety alerts for drugs, biological, medical devices and drug supplements; drugs and therapeutic biological products. Lucentis®. Barron H. Letter - January 24, 2007, Genentech [online]. Available from URL: http://www.fda.gov/Medwatch/ safety/2007/Lucentis_DHCP_01-24-2007.pdf [Accessed 2007 Feb 1]
43. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006 Apr; 113 (4): 632.e1
44. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005 Jun; 112 (6): 1048-53
45. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006 Oct; 26 (8): 859-70
46. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999 Sep-Oct; 27 (5): 536-44
47. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006 Mar; 26 (3): 257-61
48. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006 Mar; 26 (3): 262-9
49. Beer PM, Wong SJ, Hammad AM, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006 Oct; 26 (8): 871-6
50. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005 Jun; 112 (6): 1035-47
51. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006 Nov; 113 (11): e1-12
52. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006 Apr; 26 (4): 383-90
53. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006 Mar; 113 (3): 363-72
54. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006 May-Jun; 26 (5): 495-511
55. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006 Jul; 142 (1): 1-9
56. Abrahám-Marin ML, Cortés-Luna CF, Alvarez-Rivera G, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol 2007 May; 245 (5): 651-5
57. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006 Oct; 47 (10): 4569-78
58. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005 Jul-Aug; 36 (4): 331-5
59. Bom Aggio F, Eid Farah M, Melo GB. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Acta Ophthalmol Scand 2006 Oct; 84 (5): 713-4
60. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006 Mar; 26 (3): 270-4
61. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006 Nov; 90 (11): 1344-9
62. Meyer CH, Mennel S, Schmidt JC, et al. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 2006 Sep; 90 (9): 1207-8
63. Pieramici DJ, Bressler SB, Koester JM, et al. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4. Arch Ophthalmol 2006 May; 124 (5): 660-4
64. Ziemssen F, Warga M, Neuhann IM, et al. Does intravitreal injection of bevacizumab have an effect on the blood-aqueous barrier function? [letter]. Br J Ophthalmol 2006 Jul; 90 (7): 922
65. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006 Oct; 26 (8): 877-81
66. Rosenfeld PJ. Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 2006 Jul; 142 (1): 141-3
67. National Eye Institute, National Institutes of Health. News and events, NEI statement (last modified December 2006). National Institutes of Health stimulates the development and testing of new therapies for advanced age-related macular degeneration (AMD) [online]. Available from URL: http://www.nei.nih. gov/news/statements/amd_therapy.asp [Accessed 2007 Jul 3]
68. Gillies MC. What we don't know about Avastin might hurt us. Arch Ophthalmol 2006 Oct; 124 (10): 1478-9
69. Carrasquillo KG, Ricker JA, Rigas IK, et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly (lactic-coglycolic) acid microspheres. Invest Ophthalmol Vis Sci 2003 Jan; 44 (1): 290-9
70. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005 Dec 13; 57 (14): 2063-79